Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study
Phase of Trial: Phase IV
Latest Information Update: 19 Feb 2019
Price : $35 *
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SCALA
- 19 Feb 2019 Last checked against European Clinical Trials Database record.
- 14 Feb 2019 Status changed from recruiting to completed.
- 10 Jul 2014 New trial record